Working… Menu

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (STAGED-PKD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03523728
Recruitment Status : Recruiting
First Posted : May 14, 2018
Last Update Posted : October 14, 2019
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:

Primary Objective:

To determine the effect of venglustat on the rate of total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Secondary Objectives:

  • To determine the effect of venglustat on the rate of renal function decline (Stage 1) and on the rate of TKV growth (Stage 2).
  • To evaluate the pharmacokinetics (PK) of venglustat in Autosomal Dominant Polycystic Kidney Disease patients (Stages 1 and 2).
  • Safety/tolerability objective:
  • To characterize the safety profile of venglustat (Stages 1 and 2).
  • To evaluate the effect of venglustat on mood using Beck Depression Inventory II (BDI-II) (Stages 1 and 2).
  • To evaluate the effect of venglustat on the lens by ophthalmological examination (Stages 1 and 2).
  • To evaluate change in nocturia based on patient reported diary (Stages 1 and 2).
  • To evaluate the effect of venglustat on kidney concentrating ability by assessing urine osmolality (in patients not on diuretic) (Stage 2 only).

Condition or disease Intervention/treatment Phase
Polycystic Kidney, Autosomal Dominant Drug: Venglustat GZ402671 Drug: Placebo Phase 2 Phase 3

Detailed Description:
Study duration per participant is 26 months (maximal) per stage, including a screening period of 15 days, run-in period of 2 weeks, a 24-month treatment period, and a follow-up 30 days after final dose of investigational medicinal product (IMP).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 560 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Actual Study Start Date : October 4, 2018
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Experimental: Venglustat dose 1
Patients will receive venglustat dose 1 once daily for 24 months
Drug: Venglustat GZ402671
Pharmaceutical form: capsule Route of administration: oral

Experimental: Venglustat dose 2
Patients will receive venglustat dose 2 once daily for 24 months
Drug: Venglustat GZ402671
Pharmaceutical form: capsule Route of administration: oral

Placebo Comparator: Placebo
Placebo will be given once daily (Stage 1 and Stage 2) for 24 months
Drug: Placebo
Pharmaceutical form: capsule Route of administration: oral

Primary Outcome Measures :
  1. Rate of change in of total kidney volume (TKV) [ Time Frame: From baseline to 18 months ]
    Annualized rate of change in total kidney volume (TKV) based on magnetic resonance imaging (MRI) from baseline to 18 months (Stage 1)

  2. Rate of change in eGFR [ Time Frame: From baseline to 24 months ]
    Annualized rate of change in estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation) from baseline to 24 months (Stage 2)

Secondary Outcome Measures :
  1. Rate of change in eGFR [ Time Frame: From baseline to 18 months ]
    Annualized rate of change in eGFR (CKD-EPI equation) from baseline to 18 months (Stage 1)

  2. Rate of change in TKV [ Time Frame: From baseline to 18 months ]
    Annualized rate of change in TKV based on MRI from baseline to 18 months (Stage 2)

  3. Change in urine osmolality [ Time Frame: From baseline to 24 months ]
    Change in urine osmolality from baseline to 24 months (in patients not on diuretic) (Stage 2)

  4. Change in nocturia [ Time Frame: Stage 1: From baseline to 18 months; Stage 2: From baseline to 24 months ]
    Change in nocturia from baseline to 18 months (Stage 1) and from baseline to 24 months (Stage 2)

  5. Adverse events [ Time Frame: Stage 1: From baseline to 18 months; Stage 2: From baseline to 24 months ]
    Number of adverse events (Stages 1 and 2)

  6. Assessment of plasma concentration of venglustat [ Time Frame: Stage 1: Day 1, Months 1, 6, and 18; Stage 2: Months 6 and 24 ]
    Assessment of single time-point plasma concentration (Stages 1 and 2)

  7. Change in lens clarity [ Time Frame: Stage 1: From baseline to 18 months; Stage 2: From baseline to 24 months ]
    Change in the lens clarity from baseline by ophthalmological examination (Stages 1 and 2)

  8. Change in score of Beck Depression Inventory-II (BDI-II) [ Time Frame: Stage 1: From baseline to 18 months; Stage 2: From baseline to 24 months ]
    Change in score of BDI-II (Stages 1 and 2)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Male or female adult with Autosomal Dominant Polycystic Kidney Disease (ADPKD) diagnosed by unified Pei criteria between ages of 18 to 50 years (both inclusive) at screening.
  • Mayo Imaging Classification of ADPKD Class 1C, 1D or 1E (3).
  • Estimated glomerular filtration rate between 45 to 90 mL/min/1.73 m2 at screening (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]).
  • Stable treatment regimen of antihypertensive therapy for at least 30 days prior to the screening visit for hypertensive patient.
  • Able to read, comprehend, and respond to the study questionnaires.
  • Patient has given voluntary written informed consent before performance of any study related procedures not part of standard medical care.
  • Patient does not have access to tolvaptan at the time of study start or tolvaptan is not indicated for treatment of patient according to treating physician (patient does not meet recommended criteria for treatment, refuses to initiate or does not tolerate treatment with tolvaptan).
  • The patient, if female of childbearing potential, must have a negative blood pregnancy test (β-human chorionic gonadotropin [β-hCG]) at the screening visit and a negative urine pregnancy test at the baseline visit.
  • Female patients of childbearing potential and male patients must agree to practice true abstinence in line with their preferred and usual lifestyle or to use double-contraceptive methods (including a highly effective method of contraception for female participants of childbearing potential) for the entire duration of the study and for at least 6 weeks for females and 90 days for males following their last dose of study drug.

Exclusion criteria:

  • Systolic blood pressure >160 mm Hg at Run-in and Baseline visits.
  • Administration within 3 months prior to the screening visit of tolvaptan or other Polycystic Kidney Disease-modifying agents (somatostatin analogues).
  • Current participation in another investigational interventional study or use of investigational medicinal product (IMP), within 3 months or 5 half lives, whichever is longer, before randomization.
  • The patient has a documented diagnosis of any of the following infections: hepatitis B, hepatitis C, human immunodeficiency virus 1 or 2. Patients with a positive hepatitis B surface antibody (HBsAb) test with a history of prior hepatitis B immunization are eligible if other criteria are met (ie, negative tests for: HBsAg, hepatitis B core antibody [HBcAb]).Patients with positive hepatitis B core antibody [HBcAb], negative HBsAg and negative hepatitis B surface antibody (HBsAb) tests are eligible if they have HBV DNA negative test.
  • A history of drug and/or alcohol abuse within the past year prior to the screening visit.
  • The patient is scheduled for in-patient hospitalization including elective surgery, during the study.
  • The patient has a clinically significant, uncontrolled medical condition that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the condition exacerbated during the study, or that may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.
  • The patient, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (eg, has contraindications to pupillary dilation or unable to undergo magnetic resonance imaging (MRI) [For example: patient's weight exceeds weight capacity of the MRI, ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc]).
  • Any country-related specific regulation that would prevent the patient from entering the study.
  • The patients did not adhere to treatment (<70% compliance rate) in the run-in.
  • The patient has, according to World Health Organization (WHO) Grading, a cortical cataract >one-quarter of the lens circumference (Grade cortical cataract-2 [COR-2]) or a posterior subcapsular cataract >2 mm (Grade posterior subcapsular cataract-2 [PSC-2]). Patients with nuclear cataracts will not be excluded.
  • The patient is currently receiving potentially cataractogenic medications, including a chronic regimen (more frequently than every 2 weeks) of any route of corticosteroids (including medium and high potency topical steroids) or any medication that may cause cataract, according to the Prescribing Information.
  • The patient has received strong or moderate inducers or inhibitors of CYP3A4 within 14 days or 5 half-lives, whichever is longer, prior to randomization. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat administration.
  • The patient is pregnant, or lactating.
  • Liver enzymes (alanine aminotransferase [ALT]/aspartate aminotransferase [AST]) or total bilirubin >2 times the upper limit of normal unless the patient has the diagnosis of Gilbert syndrome. Patients with the Gilbert syndrome should have no additional symptoms or signs which suggest hepatobiliary disease and serum total bilirubin level no more than 3mg/dl (51 μmol/L) with conjugated bilirubin less than 20% of the total bilirubin fraction.
  • Presence of severe depression as measured by Beck Depression Inventory-II (BDI-II) >28 and/or a history of a major affective disorder within 1 year of the screening visit.
  • Known hypersensitivity to venglustat or any component of the excipients.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03523728

Layout table for location contacts
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext 1 then #

  Hide Study Locations
Layout table for location information
United States, Alabama
Investigational Site Number 8400002 Recruiting
Birmingham, Alabama, United States, 35294
United States, California
Investigational Site Number 8400017 Recruiting
Los Angeles, California, United States, 90024
United States, Colorado
Investigational Site Number 8400008 Recruiting
Aurora, Colorado, United States, 80045
United States, Connecticut
Investigational Site Number 8400010 Recruiting
New Haven, Connecticut, United States, 06510
United States, Georgia
Investigational Site Number 8400004 Recruiting
Atlanta, Georgia, United States, 30322
United States, Illinois
Investigational Site Number 8400007 Recruiting
Chicago, Illinois, United States, 60637
United States, Iowa
Investigational Site Number 8400014 Recruiting
Iowa City, Iowa, United States, 52242
United States, Kansas
Investigational Site Number 8400003 Recruiting
Kansas City, Kansas, United States, 66103
United States, Maryland
Investigational Site Number 8400021 Recruiting
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Investigational Site Number 8400016 Recruiting
Boston, Massachusetts, United States, 02111
United States, Minnesota
Investigational Site Number 8400020 Recruiting
Rochester, Minnesota, United States, 55905
United States, Texas
Investigational Site Number 8400015 Recruiting
San Antonio, Texas, United States, 78215
United States, West Virginia
Investigational Site Number 8400019 Recruiting
Morgantown, West Virginia, United States, 26506
United States, Wisconsin
Investigational Site Number 8400005 Recruiting
Madison, Wisconsin, United States, 53792
Investigational Site Number 8400006 Recruiting
Milwaukee, Wisconsin, United States, 53226
Investigational Site Number 0360002 Recruiting
Herston, Australia, 4029
Investigational Site Number 0360001 Recruiting
Westmead, Australia, 2145
Investigational Site Number 0400001 Recruiting
Graz, Austria, 8036
Investigational Site Number 0560001 Recruiting
Bruxelles, Belgium, 1200
Investigational Site Number 0560002 Recruiting
Leuven, Belgium, 3000
Investigational Site Number 1240002 Recruiting
Edmonton, Canada, T6G 2B7
Investigational Site Number 1240003 Recruiting
Montreal, Canada, H2W 1R7
Investigational Site Number 1240001 Recruiting
Toronto, Canada, M5G 2N2
Investigational Site Number 1560005 Recruiting
Beijing, China, 100853
Investigational Site Number 1560004 Recruiting
Chengdu, China, 610041
Investigational Site Number 1560002 Recruiting
Hefei, China, 230022
Investigational Site Number 1560001 Recruiting
Shanghai, China, 200003
Investigational Site Number 1560003 Recruiting
Shenyang, China, 110004
Investigational Site Number 2030001 Recruiting
Praha 2, Czechia, 12808
Investigational Site Number 2030002 Recruiting
Praha 4, Czechia, 14021
Investigational Site Number 2080001 Recruiting
København Ø, Denmark, 2100
Investigational Site Number 2080002 Recruiting
Roskilde, Denmark, 4000
Investigational Site Number 2500003 Recruiting
Brest, France, 29609
Investigational Site Number 2500002 Recruiting
Paris, France, 75743
Investigational Site Number 2500001 Recruiting
Toulouse, France, 31403
Investigational Site Number 2760001 Recruiting
Berlin, Germany, 10117
Investigational Site Number 2760002 Recruiting
Dresden, Germany, 01307
Investigational Site Number 2760007 Recruiting
Düsseldorf, Germany, 40210
Investigational Site Number 2760005 Recruiting
Hannover, Germany, 30625
Investigational Site Number 2760003 Recruiting
Köln, Germany, 50937
Investigational Site Number 2760004 Recruiting
München, Germany, 81675
Investigational Site Number 3800002 Recruiting
Milano, Italy, 20132
Investigational Site Number 3800001 Recruiting
Montichiari, Italy, 25018
Investigational Site Number 3920002 Recruiting
Bunkyo-Ku, Japan
Investigational Site Number 3920005 Recruiting
Kamakura-Shi, Japan
Investigational Site Number 3920006 Recruiting
Kawasaki-Shi, Japan
Investigational Site Number 3920010 Recruiting
Kyoto-Shi, Japan
Investigational Site Number 3920009 Recruiting
Nagoya-Shi, Japan
Investigational Site Number 3920003 Recruiting
Niigata-Shi, Japan
Investigational Site Number 3920007 Recruiting
Osaka-Shi, Japan
Investigational Site Number 3920001 Recruiting
Sapporo-Shi, Japan
Investigational Site Number 3920004 Recruiting
Shinjuku-Ku, Japan
Investigational Site Number 3920008 Recruiting
Toyoake-Shi, Japan
Korea, Republic of
Investigational Site Number 4100001 Recruiting
Seoul, Korea, Republic of, 03080
Investigational Site Number 4100002 Recruiting
Seoul, Korea, Republic of, 07061
Investigational Site Number 5280001 Recruiting
Groningen, Netherlands, 9713 GZ
Investigational Site Number 5280002 Recruiting
Nijmegen, Netherlands, 6525 GA
Investigational Site Number 6200004 Recruiting
Almada, Portugal, 2801-951
Investigational Site Number 6200001 Recruiting
Loures, Portugal, 2674-514
Investigational Site Number 6420002 Recruiting
Bucuresti, Romania, 022328
Investigational Site Number 6420001 Recruiting
Timisoara, Romania, 300723
Investigational Site Number 7240003 Recruiting
Barcelona, Spain, 08003
Investigational Site Number 7240001 Recruiting
Barcelona, Spain, 08025
Investigational Site Number 7240002 Recruiting
Madrid, Spain, 28040
Investigational Site Number 1580001 Recruiting
Taichung, Taiwan, 40447
Investigational Site Number 1580002 Recruiting
Taipei, Taiwan, 10043
United Kingdom
Investigational Site Number 8260001 Recruiting
Sheffield, United Kingdom, S5 7AU
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company Identifier: NCT03523728     History of Changes
Other Study ID Numbers: EFC15392
2017‐004084‐12 ( EudraCT Number )
U1111-1202-0775 ( Other Identifier: UTN )
First Posted: May 14, 2018    Key Record Dates
Last Update Posted: October 14, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Kidney Diseases, Cystic
Kidney Diseases
Urologic Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn